Developer docs
API playgroundTry for free, no card

Search company profiles

Amniotics

Full company profile

uuid0003eka

Namestring
Amniotics
Websiteurl
amniotics.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Amniotics is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Lund, Sweden, that develops therapeutic candidates based on mesenchymal stem cells (MSCs) isolated from amniotic fluid. The company's core technology platform leverages amniotic fluid as a non-invasive, ethically uncomplicated source of MSCs, which are then manufactured and expanded for potential use in treating serious diseases. Amniotics has positioned its pipeline within the Spinal Muscular Atrophy (SMA) treatment landscape, a rare genetic neuromuscular disorder, joining a competitive field of 18+ companies developing 20+ pipeline therapies for this indication.

The company operates as a publicly listed entity on Nasdaq (ticker: AMNI) with a small team of 1-10 employees led by CEO and founding member Marcus Larsson. Amniotics has secured early-stage funding from Almi Invest (2019) and LU Innovation (2021), reflecting support from regional Nordic investors typical of Swedish biotech ventures at the pre-clinical or early-clinical stage.

The business model is pre-commercial: Amniotics generates no product revenue and operates without distribution channels, pricing, or sales infrastructure. The company funds operations through equity capital and applies resources toward preclinical research, clinical development, regulatory engagement, and scientific publication rather than commercial activities. Any future revenue model would depend on successful clinical advancement, regulatory approval, and the establishment of pharmaceutical distribution or specialty pharmacy partnerships — none of which are currently in place. The company is a sub-scale, capital-constrained participant in a competitive rare disease therapeutic landscape, with reported operating losses declining year over year since a 2021 peak, signaling either disciplined cost management or operational contraction.

Short descriptiontext

Amniotics is a clinical-stage Swedish biopharmaceutical company developing mesenchymal stem cell (MSC) therapies derived from amniotic fluid, targeting rare diseases including Spinal Muscular Atrophy (SMA). It is pre-revenue, publicly listed on Nasdaq, and operates with a small team.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLund, Sweden
HQ citystring
Lund
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
cell therapy development, mesenchymal stem cells, amniotic fluid therapeutics, biopharmaceutical research, regenerative medicine
Industry1 code
PRIMARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Health Services8000
Product category
Cell Therapy / Biopharmaceuticals
No data
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Amniotics is a clinical-stage biopharmaceutical company that develops cell therapies based on mesenchymal stem cells (MSCs) isolated from amniotic fluid. The company is advancing a pipeline of therapeutic candidates, including a program targeting Spinal Muscular Atrophy (SMA), a rare genetic neuromuscular disorder.

Differentiator
Functional benefit
Problem solved
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

BrainStorm develops autologous stem cell therapies for neurodegenerative diseases. Comparable to Amniotics as a small clinical-stage cell therapy biotech targeting neurological/neuromuscular indications.

2Athersys
TypeDirect peer
Description

Athersys is a clinical-stage cell therapy company developing MultiStem (an MSC-like platform) for inflammatory, neurological, and pulmonary indications. Direct peer given shared MSC-class platform and clinical-stage profile.

TypeDirect peer
Description

Mesoblast is a clinical-stage cell therapy company developing mesenchymal stem cell (MSC)-based therapies for inflammatory and degenerative diseases. It is a direct peer to Amniotics given the shared MSC platform and regenerative-medicine focus.

TypeDirect peer
Description

Capricor develops cell-based therapeutics, including exosome and stem cell-derived therapies, for rare diseases including neuromuscular indications. Comparable to Amniotics in cell-therapy modality and rare-disease focus.

TypeDirect peer
Description

Scholar Rock is a clinical-stage biotech developing therapeutics for SMA and other rare diseases, including myostatin-targeting agents. Directly comparable as a peer SMA-focused clinical-stage company.

TypeDirect peer
Description

Cytokinetics develops muscle biology-targeted therapeutics including for SMA and other neuromuscular disorders. Direct peer given shared SMA indication and clinical-stage rare neuromuscular focus.

TypeBroad incumbent
Description

Biogen commercializes Spinraza, the leading approved SMA therapy. It is a broad incumbent in the same disease space and a key competitive benchmark for any new SMA entrant like Amniotics.

TypeBroad incumbent
Description

Novartis markets Zolgensma, a one-time gene therapy for SMA. As a broad incumbent in the SMA treatment landscape, Novartis defines the competitive ceiling for new SMA entrants.

TypeEmerging player
Description

PTC Therapeutics is a rare-disease focused biopharma with SMA-relevant programs (including risdiplam partnerships) and broader neuromuscular pipeline. Emerging peer given overlapping rare-disease and SMA-adjacent focus.

TypeEmerging player
Description

Ionis pioneered antisense oligonucleotide therapies and is the originator of Spinraza (licensed to Biogen). Comparable as a clinical/RNA-based neuromuscular drug developer with SMA heritage relevant to Amniotics' lead indication.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Amniotics

Cell Therapy / Biopharmaceuticalsamniotics.com

Amniotics is a clinical-stage Swedish biopharmaceutical company developing mesenchymal stem cell (MSC) therapies derived from amniotic fluid, targeting rare diseases including Spinal Muscular Atrophy (SMA). It is pre-revenue, publicly listed on Nasdaq, and operates with a small team.

What Amniotics does

Amniotics is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Lund, Sweden, that develops therapeutic candidates based on mesenchymal stem cells (MSCs) isolated from amniotic fluid. The company's core technology platform leverages amniotic fluid as a non-invasive, ethically uncomplicated source of MSCs, which are then manufactured and expanded for potential use in treating serious diseases. Amniotics has positioned its pipeline within the Spinal Muscular Atrophy (SMA) treatment landscape, a rare genetic neuromuscular disorder, joining a competitive field of 18+ companies developing 20+ pipeline therapies for this indication.

The company operates as a publicly listed entity on Nasdaq (ticker: AMNI) with a small team of 1-10 employees led by CEO and founding member Marcus Larsson. Amniotics has secured early-stage funding from Almi Invest (2019) and LU Innovation (2021), reflecting support from regional Nordic investors typical of Swedish biotech ventures at the pre-clinical or early-clinical stage.

The business model is pre-commercial: Amniotics generates no product revenue and operates without distribution channels, pricing, or sales infrastructure. The company funds operations through equity capital and applies resources toward preclinical research, clinical development, regulatory engagement, and scientific publication rather than commercial activities. Any future revenue model would depend on successful clinical advancement, regulatory approval, and the establishment of pharmaceutical distribution or specialty pharmacy partnerships — none of which are currently in place. The company is a sub-scale, capital-constrained participant in a competitive rare disease therapeutic landscape, with reported operating losses declining year over year since a 2021 peak, signaling either disciplined cost management or operational contraction.

Amniotics firmographics

Firmographics
Name
Amniotics
Website
https://amniotics.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
Amniotics is a clinical-stage Swedish biopharmaceutical company developing mesenchymal stem cell (MSC) therapies derived from amniotic fluid, targeting rare diseases including Spinal Muscular Atrophy (SMA). It is pre-revenue, publicly listed on Nasdaq, and operates with a small team.
Ownership category
akta.pro rank

Amniotics industry classification

Industry
Product category
Cell Therapy / Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Health Services (8000)
akta.pro industry
PRIMARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)

Keywords

  • Cell therapy development
  • Mesenchymal stem cells
  • Amniotic fluid therapeutics
  • Biopharmaceutical research
  • Regenerative medicine

Where Amniotics is headquartered

Location

Headquarters

HQ city
Lund
HQ country
Sweden
HQ region
Europe

Markets served

Amniotics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations

Amniotics product offering

Product offering

Core offering

Amniotics is a clinical-stage biopharmaceutical company that develops cell therapies based on mesenchymal stem cells (MSCs) isolated from amniotic fluid. The company is advancing a pipeline of therapeutic candidates, including a program targeting Spinal Muscular Atrophy (SMA), a rare genetic neuromuscular disorder.

Differentiator

Problem solved

Functional benefit

Companies that use Amniotics

Customer profile

Segments1 record

Ideal customer profiles1 record

Amniotics technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Amniotics partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves4 records

Expansion highlights3 records

Amniotics competitors and assessment

Company assessment

Direct peers

  • BrainStorm Cell Therapeutics: BrainStorm develops autologous stem cell therapies for neurodegenerative diseases. Comparable to Amniotics as a small clinical-stage cell therapy biotech targeting neurological/neuromuscular indications.
  • Athersys: Athersys is a clinical-stage cell therapy company developing MultiStem (an MSC-like platform) for inflammatory, neurological, and pulmonary indications. Direct peer given shared MSC-class platform and clinical-stage profile.
  • Mesoblast: Mesoblast is a clinical-stage cell therapy company developing mesenchymal stem cell (MSC)-based therapies for inflammatory and degenerative diseases. It is a direct peer to Amniotics given the shared MSC platform and regenerative-medicine focus.
  • Capricor Therapeutics: Capricor develops cell-based therapeutics, including exosome and stem cell-derived therapies, for rare diseases including neuromuscular indications. Comparable to Amniotics in cell-therapy modality and rare-disease focus.
  • Scholar Rock: Scholar Rock is a clinical-stage biotech developing therapeutics for SMA and other rare diseases, including myostatin-targeting agents. Directly comparable as a peer SMA-focused clinical-stage company.
  • Cytokinetics: Cytokinetics develops muscle biology-targeted therapeutics including for SMA and other neuromuscular disorders. Direct peer given shared SMA indication and clinical-stage rare neuromuscular focus.

Broad incumbents

  • Biogen: Biogen commercializes Spinraza, the leading approved SMA therapy. It is a broad incumbent in the same disease space and a key competitive benchmark for any new SMA entrant like Amniotics.
  • Novartis: Novartis markets Zolgensma, a one-time gene therapy for SMA. As a broad incumbent in the SMA treatment landscape, Novartis defines the competitive ceiling for new SMA entrants.

Emerging players

  • PTC Therapeutics: PTC Therapeutics is a rare-disease focused biopharma with SMA-relevant programs (including risdiplam partnerships) and broader neuromuscular pipeline. Emerging peer given overlapping rare-disease and SMA-adjacent focus.
  • Ionis Pharmaceuticals: Ionis pioneered antisense oligonucleotide therapies and is the originator of Spinraza (licensed to Biogen). Comparable as a clinical/RNA-based neuromuscular drug developer with SMA heritage relevant to Amniotics' lead indication.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

Amniotics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Amniotics leadership team

Management profile

Number of profiles

Profiles1 record

Amniotics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Amniotics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amniotics

What does Amniotics do?

Amniotics is a clinical-stage biopharmaceutical company that develops cell therapies based on mesenchymal stem cells (MSCs) isolated from amniotic fluid. The company is advancing a pipeline of therapeutic candidates, including a program targeting Spinal Muscular Atrophy (SMA), a rare genetic neuromuscular disorder.

Is Amniotics a public or private company?

Amniotics is a private company. It is classified as public and is currently operating.

When was Amniotics founded?

Amniotics was founded in 2015. It employs 1 to 10 people.

Where is Amniotics based?

Amniotics is headquartered in Lund, Sweden, in the Europe region.

Who are Amniotics's main competitors?

Direct peers on record are BrainStorm Cell Therapeutics, Athersys, Mesoblast, Capricor Therapeutics, Scholar Rock and Cytokinetics. Broad incumbents are Biogen and Novartis. Emerging players are PTC Therapeutics and Ionis Pharmaceuticals.

Does Amniotics have an API?

No public API is recorded for Amniotics.

What industry is Amniotics in?

Amniotics's product category is Cell Therapy / Biopharmaceuticals. Its primary akta.pro industry code is HLAAALAJ, Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening). Its NAICS code is 541714 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals